Pfizer and Valneva have added another plank of evidence in support of their Lyme disease vaccine candidate, revealing antibody levels remained elevated six months after the completion of dosing in a phase 2 clinical trial. The study randomized 585 people aged between 5 and 65 years to take a two- or three-dose course of the vaccine, VLA15, or placebo. Antibody levels fell over the six months of follow-up but remained above baseline. Source: Fierce Biotech 1/12/2022